A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation

Medicine (United States)

Volumn 95, Issue 35, 2016, Pages

  Nishikawa, Hiroki ^a   Hasegawa, Kunihiro ^a   Ishii, Akio ^a   Takata, Ryo ^a   Enomoto, Hirayuki ^a   Yoh, Kazunori ^a   Kishino, Kyohei ^a   Shimono, Yoshihiro ^a   Iwata, Yoshinori ^a   Nakano, Chikage ^a   Nishimura, Takashi ^a   Aizawa, Nobuhiro ^a   Sakai, Yoshiyuki ^a   Ikeda, Naoto ^a   Takashima, Tomoyuki ^a   Iijima, Hiroko ^a   Nishiguchi, Shuhei ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis B; Liver fibrosis; Predictive model; Serum biomarkers; Validation

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B(E) ANTIGEN; HYALURONIC ACID; MEMBRANE ANTIGEN; BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; PLANT LECTIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; WISTERIA LECTIN;

ADULT; ADVANCED FIBROSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE PLATELET RATIO INDEX; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIGESTIVE TRACT PARAMETERS; FEMALE; FIBROSIS INDEX BASED ON THE 4 FACTOR INDEX; FORNS INDEX; HUMAN; HUMAN TISSUE; LIMIT OF QUANTITATION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; VALIDATION STUDY; BLOOD; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ANTIGENS, NEOPLASM; BIOMARKERS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MODELS, STATISTICAL; PLANT LECTINS; PLATELET COUNT; RECEPTORS, N-ACETYLGLUCOSAMINE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84987771037     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004679     Document Type: Article

References (33)

1. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
2. Lin CL, Tseng TC, Kao JH. What can we learn from hepatitis B virus clinical cohorts? Liver Int 2015;35(suppl 1):91-9.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365: 1118-27.
4. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 2015;61:292-302.
5. Osaki Y, NishikawaH. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res 2015;45:59-74.
6. van Meer S, de Man RA, Siersema PD, et al. Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol 2013;19:6744-56.
7. Xu XY, Kong H, Song RX, et al. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One 2014;9:e100182.
8. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis Crelated fibrosis: an updated meta-analysis. Hepatology 2011;53:726-36.
9. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6.
10. Fujiyoshi M, Kuno A, Gotoh M, et al. Hepatitis Glyco-biomarker Study GroupClinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serummarker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015;50:1134-44.
11. Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014;60:1563-70.
12. Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol 2015;50:76-84.
13. Tamaki N, Kurosaki M, Kuno A, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 2015;45:E82-8.
14. Ura K, Furusyo N, Ogawa E, et al. Serum WFA(+)-M2BP is a noninvasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther 2016;43:114-24.
15. Imbert-Bismut F, Ratziu V, Pieroni L, et al. MULTIVIRC GroupBiochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357: 1069-75.
16. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
17. Rosenberg WM, Voelker M, Thiel R, et al. European Liver Fibrosis GroupSerum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
18. KodaM,Matunaga Y, KawakamiM, et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306.
19. Valva P, Ríos DA, De Matteo E, et al. Chronic hepatitis C virus infection: serum biomarkers in predicting liver damage. World J Gastroenterol 2016;22:1367-81.
20. Branchi F, Conti CB, Baccarin A, et al. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2014;20: 14568-80.
21. Enomoto M, Morikawa H, Tamori A, et al. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2014;20:12031-8.
22. Kuno A, Ikehara Y, Tanaka Y, et al. A serum sweet-doughnut 272 protein facilitates fibrosis evaluation and therapy assessment in patients 273 with viral hepatitis. Sci Rep 2013;3:1065.
23. Kuno A, Sato T, Shimazaki H, et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 2013;7:642-7.
24. Ishii A, Nishikawa H, Enomoto H, et al. Clinical implication of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment naïve chronic hepatitis B. Hepatol Res 2016;[Epub ahead of print].
25. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73.
26. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-47.
27. Li Y, Huang YS, Wang ZZ, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther 2016;43:458-69.
28. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-74.
29. Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in west Africa. Gut 2016;65:1369-76.
30. Zhou K,Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2010;25:1569-77.
31. Wu SD, Ni YJ, Liu LL, et al. Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2012;6:360-8.
32. Nishikawa H, Enomoto H, Iwata Y, et al. Clinical implication of serum WFA+-M2BP level on Hepatitis B e Antigen loss or Seroconversion in Hepatitis B e Antigen-positive patients. Hepatol Res 2016;doi: 10. 1111/ hepr. 12655. [Epub ahead of print].
33. Toyoda H, Kumada T, Tada T, et al. Serum WFA(+)-M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int 2016;36:293-301.